Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

What is known and objective The purpose of this review paper is to review the efficacy and
safety of subcutaneous semaglutide, marketed as Wegovy, a glucagon‐like peptide‐1 …

Abstract Losses of 5–10% or more of initial body weight are associated with improvements
in obesity-related comorbidities. However, attaining and sustaining this level of weight loss …

Obesity is a chronic, recurring, progressive disease and a major public health problem
associated with several other diseases that lead to disability, morbidity, and mortality. The …

Obesity is a global health challenge. It is a multifactorial, complex, and progressive disease
associated with various health complications and increased mortality. Lifestyle modifications …

Background Research on semaglutide's effect on weight loss has been largely focused on
Type 2 Diabetics. No meta-analyses of semaglutide's efficacy in non-diabetic individuals …

Background The weight loss benefit of semaglutide in patients with diabetes is well-
documented, but its clinical utility in treating obesity among patients without diabetes is less …